Literature DB >> 2849601

Effects of azole antifungals in vitro on host/parasite interactions relevant to Candida infections.

F C Odds1, C E Webster.   

Abstract

Clotrimazole, fluconazole, itraconazole and ketoconazole were tested for their influence on three aspects of host/parasite interactions in the context of Candida infections. None of clotrimazole, itraconazole or ketoconazole had any effect on the adherence of C. albicans to vaginal epithelial cells, in vitro, regardless of whether the drugs were used to pretreat the fungi or the vaginal cells or were added to the fungus/vaginal cell mixture. Clotrimazole pretreatment of polymorphonuclear leucocytes led to a marked suppression of their ability to phagocytose and kill C. albicans, but fluconazole and ketoconazole had no similar effect. None of these three antifungals affected phagocytosis or killing when they were added to the leucocyte candida mixture or when used to pretreat the fungi. Clotrimazole and ketoconazole both reduced proliferative responses of lymphocyte suspensions to mitogens but fluconazole showed no anti-lymphocyte effect. This difference in action against lymphocytes may help to explain the known disparity between the antifungal effects of fluconazole and ketoconazole against C. albicans in vivo and against experimental candida infections in vitro. Clotrimazole effected a suppression of ATP concentrations in lymphocytes but fluconazole and ketoconazole had no similar effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849601     DOI: 10.1093/jac/22.4.473

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

Review 1.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 2.  Fluconazole in the treatment of fungal infections associated with AIDS.

Authors:  S De Wit; N Clumeck
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

Review 3.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 4.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

5.  Candida albicans Iff11, a secreted protein required for cell wall structure and virulence.

Authors:  Steven Bates; José M de la Rosa; Donna M MacCallum; Alistair J P Brown; Neil A R Gow; Frank C Odds
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

6.  Candida albicans adhesion to and invasion and damage of vaginal epithelial cells: stage-specific inhibition by clotrimazole and bifonazole.

Authors:  Betty Wächtler; Duncan Wilson; Bernhard Hube
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

Review 7.  The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.

Authors:  T E Jones
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

Review 8.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

9.  Synergy of itraconazole with macrophages in killing Blastomyces dermatitidis.

Authors:  E Brummer; P R Bhagavathula; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes.

Authors:  A Pascual; I García; C Conejo; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.